Literature DB >> 12848319

Traumatic brain injury in infants and children: mechanisms of secondary damage and treatment in the intensive care unit.

Hülya Bayir1, Patrick M Kochanek, Robert S B Clark.   

Abstract

Unfortunately no specific pharmacologic therapies are available for the treatment of TBI in patients. Current investigation of contemporary therapies for the treatment of TBI consists of recycling of previously tested therapies in the era of contemporary neurointensive care. These therapies include hypothermia, decompressive craniectomy, osmotherapy, and controlled hyperventilation. It is hoped that more detailed knowledge regarding the dominant pathophysiologic mechanisms associated with TBI-excitotoxicity, CBF dysregulation, oxidative stress, and programmed cell death-will catapult an efficacious intervention from the laboratory bench to the bedside. This intervention may be a potent agent targeting a single dominant pathway, a broad-spectrum intervention such as hypothermia, or, more likely, a combination of therapies. Meanwhile, practitioners must offer meticulous supportive neurointensive care using clinically proven therapies aimed at minimizing cerebral swelling for the management of pediatric patients who are victims of TBI.

Entities:  

Mesh:

Year:  2003        PMID: 12848319     DOI: 10.1016/s0749-0704(03)00014-9

Source DB:  PubMed          Journal:  Crit Care Clin        ISSN: 0749-0704            Impact factor:   3.598


  22 in total

1.  Physiological and histopathological responses following closed rotational head injury depend on direction of head motion.

Authors:  Stephanie A Eucker; Colin Smith; Jill Ralston; Stuart H Friess; Susan S Margulies
Journal:  Exp Neurol       Date:  2010-09-25       Impact factor: 5.330

Review 2.  Hypothermia following pediatric traumatic brain injury.

Authors:  P David Adelson
Journal:  J Neurotrauma       Date:  2009-03       Impact factor: 5.269

Review 3.  Decompressive Craniectomy and Traumatic Brain Injury: A Review.

Authors:  Hernando Alvis-Miranda; Sandra Milena Castellar-Leones; Luis Rafael Moscote-Salazar
Journal:  Bull Emerg Trauma       Date:  2013-04

Review 4.  Neuroprotection in Oxidative Stress-Related Neurodegenerative Diseases: Role of Endocannabinoid System Modulation.

Authors:  Janos Paloczi; Zoltan V Varga; George Hasko; Pal Pacher
Journal:  Antioxid Redox Signal       Date:  2017-07-18       Impact factor: 8.401

5.  Microglial inhibitory effect of ginseng ameliorates cognitive deficits and neuroinflammation following traumatic head injury in rats.

Authors:  Anil Kumar; Puneet Rinwa; Hitesh Dhar
Journal:  Inflammopharmacology       Date:  2013-09-20       Impact factor: 4.473

Review 6.  Natural Compounds as a Therapeutic Intervention following Traumatic Brain Injury: The Role of Phytochemicals.

Authors:  Stephen W Scheff; Mubeen A Ansari
Journal:  J Neurotrauma       Date:  2016-12-21       Impact factor: 5.269

Review 7.  The endocannabinoid system as an emerging target of pharmacotherapy.

Authors:  Pál Pacher; Sándor Bátkai; George Kunos
Journal:  Pharmacol Rev       Date:  2006-09       Impact factor: 25.468

8.  Cyclosporin A preserves mitochondrial function after traumatic brain injury in the immature rat and piglet.

Authors:  Todd J Kilbaugh; Sunita Bhandare; David H Lorom; Manda Saraswati; Courtney L Robertson; Susan S Margulies
Journal:  J Neurotrauma       Date:  2011-04-12       Impact factor: 5.269

9.  Is decompressive craniectomy for malignant middle cerebral artery infarction of any worth?

Authors:  Xiao-feng Yang; Yu Yao; Wei-wei Hu; Gu Li; Jin-fang Xu; Xue-qun Zhao; Wei-guo Liu
Journal:  J Zhejiang Univ Sci B       Date:  2005-07       Impact factor: 3.066

10.  Disruption of Bax protein prevents neuronal cell death but produces cognitive impairment in mice following traumatic brain injury.

Authors:  Roya Tehranian; Marie E Rose; Vincent Vagni; Alicia M Pickrell; Raymond P Griffith; Hao Liu; Robert S B Clark; C Edward Dixon; Patrick M Kochanek; Steven H Graham
Journal:  J Neurotrauma       Date:  2008-07       Impact factor: 5.269

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.